5 results on '"Suppes, Trisha"'
Search Results
2. Adaptive cognitive control circuit changes associated with problem-solving ability and depression symptom outcomes over 24 months.
- Author
-
Zhang, Xue, Pines, Adam, Stetz, Patrick, Goldstein-Piekarski, Andrea N., Xiao, Lan, Lv, Nan, Tozzi, Leonardo, Lavori, Philip W., Snowden, Mark B., Venditti, Elizabeth M., Smyth, Joshua M., Suppes, Trisha, Ajilore, Olusola, Ma, Jun, and Williams, Leanne M.
- Subjects
PROBLEM-solving therapy ,FUNCTIONAL magnetic resonance imaging ,TREATMENT effect heterogeneity ,CONTROL (Psychology) ,COGNITIVE ability - Abstract
Mechanistically targeted behavioral interventions are a much-needed strategy for improving outcomes in depression, especially for vulnerable populations with comorbidities such as obesity. Such interventions may change behavior and outcome by changing underlying neural circuit function. However, it is unknown how these circuit-level modifications unfold over intervention and how individual differences in early circuit-level modifications may explain the heterogeneity of treatment effects. We addressed this need within a clinical trial of problem-solving therapy for participants with depression symptoms and comorbid obesity, focusing on the cognitive control circuit as a putative neural mechanism of action. Functional magnetic resonance imaging was applied to measure the cognitive control circuit activity at five time points over 24 months. Compared with participants who received usual care, those receiving problem-solving therapy showed that attenuations in cognitive control circuit activity were associated with enhanced problem-solving ability, which suggests that this circuit plays a key role in the mechanisms of problem-solving therapy. Attenuations in circuit activity were also associated with improved depression symptoms. Changes in cognitive control circuit activity at 2 months better predicted changes in problem-solving ability and depression symptoms at 6, 12, and 24 months, with predictive improvements ranging from 17.8 to 104.0%, exceeding baseline demographic and symptom characteristics. Our findings suggest that targeting the circuit mechanism of action could enhance the prediction of treatment outcomes, warranting future model refinement and improvement to pave the way for its clinical application. Editor's summary: Behavioral intervention therapies can improve symptoms of depression but do not work for all patients. To identify brain circuit changes that might underlie treatment response, Zhang et al. performed a longitudinal fMRI imaging study on patients with depression and comorbid obesity who received either problem-solving therapy (I-CARE) or usual care (U-CARE). They found that decreased cognitive control circuit activity measured at different time points over 24 months correlated with better treatment outcomes. A predictive model based on control circuit changes at 2 months outperformed a standard model based on demographic and clinical parameters. These results suggest an approach that could support treatment outcome predictions for depression, but further optimization and validation are needed. —Daniela Neuhofer [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.
- Author
-
Aaronson, Scott T., van der Vaart, Andrew, Miller, Tammy, LaPratt, Jeffrey, Swartz, Kimberly, Shoultz, Audrey, Lauterbach, Margo, Sackeim, Harold A., and Suppes, Trisha
- Subjects
PSILOCYBIN ,HYPOMANIA ,PSYCHOTHERAPY ,BIPOLAR disorder ,COLUMBIA-Suicide Severity Rating Scale ,PSYCHIATRIC drugs - Abstract
Key Points: Question: Will a single psychedelic dose of psilocybin with psychotherapy demonstrate evidence for efficacy and/or safety in drug-free, treatment-resistant participants with bipolar II depression? Findings: In this nonrandomized open-label trial of 15 individuals with bipolar II depression, most participants met remission criteria on the Montgomery-Åsberg Depression Rating Scale 3 weeks after a single 25-mg psilocybin dose, and most remained in remission 12 weeks postdose with no increase in mania/hypomania symptoms or suicidality. Meaning: The findings suggest efficacy and safety of psilocybin in bipolar II depression and support further study of psychedelics in this population. This open-label nonrandomized open-label trial evaluates the safety and efficacy of single-dose psilocybin with psychotherapy for depressive episodes in individuals with bipolar disorder. Importance: Bipolar II disorder (BDII) is a debilitating condition frequently associated with difficult-to-treat depressive episodes. Psilocybin has evidence for rapid-acting antidepressant effects but has not been investigated in bipolar depression. Objective: To establish the safety and efficacy of psilocybin in patients with BDII in a current depressive episode. Design, Setting, and Participants: This was a 12-week, open-label nonrandomized open-label trial conducted at Sheppard Pratt Hospital. Participants aged 18 to 65 years with BDII, a current depressive episode longer than 3 months, and documented insufficient benefit with at least 2 pharmacologic treatments during the current episode were invited to participate. Of 70 approached, 19 met inclusion criteria and were enrolled. The trial was conducted between April 14, 2021, and January 5, 2023. Interventions: A single dose of synthetic psilocybin, 25 mg, was administered. Psychotropic medications were discontinued at least 2 weeks prior to dosing. Therapists met with patients for 3 sessions during pretreatment, during the 8-hour dosing day, and for 3 integration sessions posttreatment. Main Outcomes and Measures: The primary outcome measure was change in Montgomery-Åsberg Depression Rating scale (MADRS) at 3 weeks posttreatment. Secondary measures included MADRS scores 12 weeks posttreatment, the self-rated Quick Inventory of Depression Symptoms-Self Rating (QIDS-SR), and the self-rated Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF), each completed at baseline and all subsequent visits. Safety measures included the Columbia Suicide Severity Rating Scale (CSSRS) and the Young Mania Rating Scale (YMRS) completed at each visit. Results: Of the 15 participants in this study (6 male and 9 female; mean [SD] age, 37.8 [11.6] years), all had lower scores at week 3, with a mean (SD) change of −24.00 (9.23) points on the MADRS, (Cohen d = 4.08; 95% CI, −29.11 to −18.89; P <.001). Repeat measures analysis of variance showed lower MADRS scores at all tested posttreatment time points, including the end point (Cohen d = 3.39; 95% CI, −33.19 to −16.95; adjusted P <.001). At week 3, 12 participants met the response criterion (50% decrease in MADRS), and 11 met remission criterion (MADRS score ≤10). At the study end point, 12 patients met both response and remission criteria. QIDS-SR scores and Q-LES-Q-SF scores demonstrated similar improvements. YMRS and CSSRS scores did not change significantly at posttreatment compared to baseline. Conclusions and Relevance: The findings in this open-label nonrandomized open-label trial suggest efficacy and safety of psilocybin with psychotherapy in BDII depression and supports further study of psychedelics in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. The relationship between circadian gene single nucleotide polymorphisms and clinical and behavioral assessments of sleep and rhythms and course of illness characteristics in subjects with bipolar type I disorder
- Author
-
Gonzalez, Robert, Gonzalez, Suzanne D., Gupta, Jayanta, Mallawaarachchi, Indika, and Suppes, Trisha
- Published
- 2024
- Full Text
- View/download PDF
5. Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.
- Author
-
Ellis S, Bostian C, Feng W, Fischer E, Schwartz G, Eisen K, Lean M, Conlan E, Ostacher M, Aaronson S, and Suppes T
- Abstract
Background: The enduring and severe depression often suffered by Veterans causes immense suffering and is associated with high rates of suicide and disability. This is the first study to evaluate the efficacy and safety of psilocybin in Veterans with severe treatment-resistant depression (TRD)., Methods: 15 Veterans with severe TRD (major depressive episode failing to respond to ≥5 treatments, or lasting >2 years) received 25 mg of psilocybin. Primary outcome was change in Montgomery-Åsberg Depression Rating scale (MADRS) at 3 weeks posttreatment. Response was defined s ≥ 50 % reduction in MADRS, and remission as ≤10 MADRS score. Psychedelic experience was assessed using the Five-Dimensional Altered States of Consciousness scale (5D-ASC). Safety measures included assessment of suicidality and adverse events. Participants on antidepressants were tapered to avoid drug interactions., Results: Of 15 participants, 60 % met response and 53 % met remission criteria at Week 3. At 12 weeks, 47 % maintained response, and 40 % remission. Co-morbid PTSD did not significantly influence study outcomes. The psychedelic experience reported in 5D-ASC did not correlate with response. Participants judged to need antidepressants were restarted and considered non-responders from that timepoint (n = 4). No unexpected adverse events occurred., Limitations: Limitations include the small sample size, and the uncontrolled and unblinded nature of the study., Conclusions: In this first study on psilocybin for Veterans with severe TRD, a surprising response and remission was seen. Many Veterans had PTSD though no moderating impact of response was observed. The degree of psychedelic experience did not correlate with depression changes. Further study is warranted., Trial Registration: ClinicalTrials.gov Identifier: NCT04433858., Competing Interests: Declaration of competing interest TS reported stock options from Psilotec outside the submitted work. ML served as a paid consultant in therapy training for Compass Pathways during the conduct of the study. MO is a consultant for Neurocrine. SA reported grants and nonfinancial support (supply of drug) from Compass Pathways during the conduct of the study and personal fees from LivaNova, Neuronetics, Genomind, and Sage Therapeutics outside the submitted work. No other disclosures were reported., (Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.